Reneo Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	26.44	16.14	11.65	3.61	2.38
Research & Development	56.61	37.71	28.17	15.94	13.1
Operating Expenses	83.05	53.85	39.82	19.55	15.47
Operating Income	-83.05	-53.85	-39.82	-19.55	-15.47
Other Expense / Income	-5.67	-1.89	-0.05	-0.09	-3.04
Pretax Income	-77.39	-51.96	-39.77	-19.47	-12.44
Net Income	-77.39	-51.96	-39.77	-19.47	-12.44
Shares Outstanding (Basic)	31	24	18	2	2
Shares Outstanding (Diluted)	31	24	18	2	2
Shares Change	25.23%	35.01%	794.56%	4.11%	-
EPS (Basic)	-2.52	-2.12	-2.19	-9.60	-6.38
EPS (Diluted)	-2.52	-2.12	-2.19	-9.60	-6.38
Free Cash Flow	-63.9	-47.71	-38.18	-18.56	-12.52
Free Cash Flow Per Share	-2.08	-1.95	-2.10	-9.15	-6.42
EBITDA	-76.86	-51.43	-39.72	-19.43	-12.4
Depreciation & Amortization	0.53	0.53	0.05	0.04	0.03
EBIT	-77.39	-51.96	-39.77	-19.47	-12.44

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).